We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · March 23, 2021

Androgen Deprivation Therapy ± Palbociclib in RB-Positive Metastatic Hormone-Sensitive Prostate Cancer

Clinical Cancer Research


Additional Info

Clinical Cancer Research
A Randomized Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Clin. Cancer Res 2021 Mar 16;[EPub Ahead of Print], PL Palmbos, S Daignault-Newton, SA Tomlins, et al

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading